Instruction for use: Aurorix

Dosage form: coated tablets

Active substance: Moclobemide*

ATX

N06AG02 Moclobemid

Pharmacological group:

Antidepressant

The nosological classification (ICD-10)

F32 Depressive episode: Adynamic subdepression; Astheno-adynamic subdepressive states; Asthenoadressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Major Depressive Disorder; Vyaloapatichesky depression with retardation; Double Depression; Depressive pseudodement; Depressive illness; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive disorders; Depressive syndrome; Depressive syndrome larviated; Depressive syndrome in psychoses; Depressed masks; Depression; Depression Depletion; Depression with the phenomena of inhibition within the framework of cyclothymia; Depression is smiling; Involutional depression; Involutionary melancholy; Involutional depression; Manic-depressive disorder; Masked Depression; Melancholic Attack; Neurotic depression; Neurotic depression; Shallow Depression; Organic depression; Organic depressive syndrome; Simple depression; Simple melancholic syndrome; Psychogenic depression; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Reactive depression; Recurrent depression; Seasonal depressive syndrome; Severostatic depression; Senile Depression; Symptomatic Depression; Somatogenic depression; Cyclotymic depression; Exogenous depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome

F40.0 Agoraphobia: Fear of open space; Fear of being in a crowd

Composition and release form

1 dragee contains clomipramine 25 mg; in the package of 30 pcs.

1 ampoule with 2 ml solution for injection - 25 mg; in the package 10 pcs.

Pharmachologic effect

Mode of action - antidepressant.

Indication of drug Aurorix

1 tablet, coated, contains moclobemide 150 or 300 mg; in the blister 10 pcs., in the box 3 blisters.

Pharmachologic effect

Pharmacological action - antidepressive, psychostimulating.

Reversibly inhibits MAO A, inhibits the metabolism of noradrenaline, dopamine, serotonin, which leads to an increase in extracellular concentrations of these neurotransmitters.

Pharmacodynamics

Improves mood and psychomotor activity; weaken the symptoms of depression - dysphoria, nervous exhaustion, inhibition, inability to concentrate attention; Copes symptoms of social phobia.

Indication of the drug Aurorix

Depressive syndromes, social phobia.

Contraindications

Hypersensitivity, acute disturbance of consciousness, children's age, simultaneous reception of selegiline.

Application in pregnancy and lactation

Contraindicated.

Side effects

Sleep disorder, agitation, anxiety, irritability, dizziness, headache, paresthesia, visual impairment, dry mouth, gastrointestinal disturbances, skin reactions, signs of confusion (quickly disappear after drug withdrawal).

Interaction

Strengthens and lengthens the effect of sympathomimetics and, possibly, opiates. Increases the likelihood of adverse reactions from the central nervous system when combined with pethidine, clomipramine, dextromethorphan. Cimetidine slows biotransformation.

Dosing and Administration

Inside, after eating. Depression: 300-600 mg for 2-3 doses, the initial daily dose of 300 mg, with severe depressions can be increased to 600 mg. The dose is raised not earlier than 1 week after the start of treatment. When the clinical effect is obtained, the dose is reduced.

Sociophobia: 600 mg per day in 2 divided doses; the initial dose is 300 mg per day, from 4 days the dose is increased to 600 mg per day. Admission to 300 mg per day for more than 3 days is not recommended.

Storage conditions for Aurorix

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of Aurorix

5 years.

Do not use after the expiry date printed on the package.